Navacaprant
| Clinical data | |
|---|---|
| Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C25H32FN5O2 |
| Molar mass | 453.562 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder and bipolar depression.[1] [2] [3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.[2] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.[2] [4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.[5]
See also
[edit ]References
[edit ]- ^ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020年01月25日. Retrieved 2020年01月25日.
- ^ a b c "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020年01月25日.
- ^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531 . PMID 30707578.
- ^ Neumora Therapeutics, Inc. (2024年02月20日). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
- ^ a b Taylor, Nick Paul (2 January 2025). "Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%". Fierce Biotech. Retrieved 7 March 2025.
External links
[edit ]
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.